Shenzhen Kangtai Biological Products Co., Ltd.

SZSE:300601 Stock Report

Market Cap: CN¥16.1b

Shenzhen Kangtai Biological Products Future Growth

Future criteria checks 5/6

Shenzhen Kangtai Biological Products is forecast to grow earnings and revenue by 37.1% and 21.7% per annum respectively. EPS is expected to grow by 37.3% per annum. Return on equity is forecast to be 10% in 3 years.

Key information

37.1%

Earnings growth rate

37.3%

EPS growth rate

Biotechs earnings growth57.2%
Revenue growth rate21.7%
Future return on equity10.0%
Analyst coverage

Good

Last updated15 Jan 2025

Recent future growth updates

Recent updates

Market Cool On Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Earnings

Jan 17
Market Cool On Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Earnings

Investors Appear Satisfied With Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Prospects As Shares Rocket 32%

Oct 13
Investors Appear Satisfied With Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Prospects As Shares Rocket 32%

Here's Why Shenzhen Kangtai Biological Products (SZSE:300601) Has A Meaningful Debt Burden

Sep 25
Here's Why Shenzhen Kangtai Biological Products (SZSE:300601) Has A Meaningful Debt Burden

These Analysts Just Made A Massive Downgrade To Their Shenzhen Kangtai Biological Products Co., Ltd. (SZSE:300601) EPS Forecasts

Sep 02
These Analysts Just Made A Massive Downgrade To Their Shenzhen Kangtai Biological Products Co., Ltd. (SZSE:300601) EPS Forecasts

Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Share Price Not Quite Adding Up

Aug 13
Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Share Price Not Quite Adding Up

Shenzhen Kangtai Biological Products (SZSE:300601) Seems To Use Debt Quite Sensibly

May 25
Shenzhen Kangtai Biological Products (SZSE:300601) Seems To Use Debt Quite Sensibly

Shenzhen Kangtai Biological Products' (SZSE:300601) Promising Earnings May Rest On Soft Foundations

May 03
Shenzhen Kangtai Biological Products' (SZSE:300601) Promising Earnings May Rest On Soft Foundations

Earnings Report: Shenzhen Kangtai Biological Products Co., Ltd. Missed Revenue Estimates By 49%

May 01
Earnings Report: Shenzhen Kangtai Biological Products Co., Ltd. Missed Revenue Estimates By 49%

Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Share Price Matching Investor Opinion

Feb 27
Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Share Price Matching Investor Opinion

Earnings and Revenue Growth Forecasts

SZSE:300601 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20264,8371,2001,2691,3546
12/31/20254,2031,1106761,2566
12/31/20243,1676285259494
9/30/20243,03151575644N/A
6/30/20242,949516133751N/A
3/31/20243,181710128828N/A
12/31/20233,4778613151,033N/A
9/30/20233,057361121911N/A
6/30/20233,060257-112777N/A
3/31/20233,034-201-326735N/A
1/1/20233,157-133-765546N/A
9/30/20223,840430-1,062953N/A
6/30/20224,4281,047-7491,711N/A
3/31/20224,2471,512-8311,770N/A
1/1/20223,6521,263-8881,652N/A
9/30/20213,2181,282-1,349891N/A
6/30/20212,443756-1,361463N/A
3/31/20212,361702-1,219337N/A
12/31/20202,261679-787440N/A
9/30/20201,96957778746N/A
6/30/20202,006576-35407N/A
3/31/20201,779477155441N/A
12/31/20191,943575119506N/A
9/30/20191,91149082446N/A
6/30/20191,761407-23387N/A
3/31/20191,955426-114325N/A
12/31/20182,017436-7336N/A
9/30/20181,867435-32281N/A
6/30/20181,756431N/A277N/A
3/31/20181,418296N/A202N/A
12/31/20171,161215N/A154N/A
9/30/20171,006168N/A99N/A
6/30/2017816101N/A35N/A
3/31/201755252N/A41N/A
12/31/201655286N/A78N/A
9/30/201646086N/A165N/A
12/31/201545363N/A278N/A
12/31/201430331N/A112N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 300601's forecast earnings growth (37.1% per year) is above the savings rate (2.8%).

Earnings vs Market: 300601's earnings (37.1% per year) are forecast to grow faster than the CN market (25% per year).

High Growth Earnings: 300601's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 300601's revenue (21.7% per year) is forecast to grow faster than the CN market (13.3% per year).

High Growth Revenue: 300601's revenue (21.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 300601's Return on Equity is forecast to be low in 3 years time (10%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 18:33
End of Day Share Price 2025/01/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shenzhen Kangtai Biological Products Co., Ltd. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pei ChengChina Galaxy Securities Co., Ltd.
Diandian LiChina Merchants Securities Co. Ltd.
Bing ZhaoChina Renaissance Securities